Theoretically, GLP1-RAs that have cardiovascular benefits and provide additional effects on visceral adiposity may be considered and have promising treatment in clinical settings, particularly for those with existing or higher risk of cardiovascular disease. The gene discussed is GLP1R; the disease is cardiovascular disorder.